Oncology Exploration Center By Alcimed

let’s face the challenges of Oncology

Alcimed has developed a recognized expertise in the field of Oncology and supports industry leaders in their innovation and new business projects.

In the field of Oncology, several factors drive continuous innovation around treatment or care. Perhaps the main driver is the very strong unmet medical need. Often being a chronic disease, cancer affects a very high number of people.

The disease itself brings strong burden on the patient in the form of disease-related symptoms, which again is aggravated often by strong side effects of treatments, ultimately resulting in a very negative impact on his/her quality of life (QoL). The diagnosis cancer can, depending on the type and stage, substantially influence QoL not only for the patient but also for one’s relatives who must deal with e.g. the mental impact of the diagnosis and possibly care for their dependent.


Key trends in cancer research and care

Cancer care today is often a disease requiring complex care processes as care depends on many factors. Patients have a wide variability in the states and progression of the disease, treatment options, points of beginning and end of a treatment, and usually require a multidisciplinary approach to their care.

This can be reached, of course, by novel, innovate treatment approaches, drugs, or devices. It can also be achieved by truly value-based treatment approaches that put the patient into the center of cancer care.

Elements such as multidisciplinary interaction, the usage of patient reported outcomes (PRO) and big patient data in general for outcome measurements, or shared decision making between physicians and patients will play a key role in cancer care of the future.

At your side to design and implement
the solutions of tomorrow.

For over 30 years, Alcimed has been dealing with numerous Oncology issues and pathologies. In fact, we have conducted more than 120 projects in Oncology in the last 5 years only.

Example of recent projects carried out for our clients in oncology

  • Clinical development and launch strategy of an Oncology asset

    Alcimed supported a top pharma player in defining the strategy of an early asset in rare cancer indication.

    We helped our client to understand the current treatment pathways in addition to needs and challenges linked to it, identified trends in the indication, and aimed to understand how these trends and underlying future technologies will impact the current treatment pathway and shape it in the future. We also worked on the evaluation of direct and indirect competitors and collaborated on the development of the short- and mid-term asset strategies.

    Our work allowed our client to optimally plan clinical trials and prepare the launch of the asset.

  • Understanding the patient pathway in the treatment of childhood cancer

    Alcimed supported a pharma player in preparing the launch of their new oncology product for pediatric patients in Germany.

    We helped them to understand the treatment pathway of childhood cancer in general from diagnosis to treatment to monitoring, even after children become adolescent. We identified key blocking points along the pathways, and mapped treatment and diagnosis centers and key stakeholders in Germany. This included patient associations, physicians, or social workers and allowed our client to optimally plan activities to support the launch of the new drug.


  • Market entry support for CAR-T cell therapy

    Alcimed supported a leading stakeholder in the field of CAR-T cells in preparing for the launch of its new treatment and in defining its market access strategy in the United States, Canada and Europe.

    CAR-T cells are highly personalized technologies that require a high level of specialization to be delivered to patients, and therefore not all healthcare facilities are ready to administer them. In this context, and in order to define the market access strategy for its new treatment, we helped our client to understand and identify which centers would have the capacity to deliver CAR-T cells, among more than 200 care centers in the United States, Canada and Europe.

    Then, the analysis of the barriers to approval in the relevant markets made it possible to define the actions to be implemented to develop the skills of each center, and thus ensure access to their new CAR-T cell therapy.

  • Development strategy of a medical device in cancer surgery

    Alcimed supported a medical device player in building adequate business models of a new intraoperative surgical technology for cancer.

    We identified the most relevant launch countries for the technology and analyzed the value of the technology for stakeholders in the scope countries, where we took into account country-specific funding mechanisms of surgeries and medical equipment. Then, Alcimed identified potential direct and indirect competitors, analyzed pressure from these players, and analyzed the commercialization potential according to needs, competitive pressure, and pricing.

  • Opportunity evaluation in immune oncology

    Alcimed supported a pharmaceutical player to analyze the opportunities to invest into the immuno-oncology field.

    We reviewed the different types of immunotherapies in cancer treatments to understand products in development, products commercialized, study on the partnerships/deals, and helped our client to estimate the market attractiveness for specific indications – notably, by reviewing pipelines and strategies of main actors, and rising stars in this field.

  • Analysis of the future potential of mCRC biomarkers

    Alcimed supported a client in deciding the future of colorectal cancer biomarkers and the potential of a new screening biochip.

    Alcimed carried out a qualitative analysis of the current and future needs of GPs and specialists who are involved in the diagnosis of colorectal cancer, as well as analyzing the strengths and weaknesses of our client offer compared to existing diagnosis methods and future molecular tests.

  • Optimizing mCRPC treatment processes and workflows in hospitals

    Alcimed supported a global pharma player in in improving mCRPC treatment processes and workflows in Nuclear Medicine Centers (NMC) in Europe.

    We helped our client by analyzing data from observations within 11 European key NMC and gathered insight into the key barriers, best practices, tools, and services that are applied in these centers. All centers gathered in an international workshop, developed means to share best practices across all European treatment centers, and published the results in an international publication. As a next step, Alcimed followed up with several centers in order to understand the level of implementation of specific solutions and their impact of the work flow in NMCs in Europe. Lastly, the entire analysis expanded to a total of around 50 European centers, and tools and outputs were enriched and updated.

    The entire project helped European centers to optimize their treatment processes.

  • Developing customer-engagement models in hemato-oncology

    Alcimed supported a client in imagining and building a brand new conviction system for its 5 future launches in hemato-oncology.

    We supported our client in understanding their expectations and needs around access to information, digital tools, and interaction with the industry and with other healthcare professionals. We then identified criteria considered important in the decision-making process of prescription in different product contexts. Finally, our team benchmarked surrogates within the pharma industry and supported our client in co-building a new conviction-engagement model.

  • Technology scouting to foster R&D

    Alcimed supported a pharma player to investigate the Immunogenic cell death (ICD) field to find future therapeutic treatments for cancer patients. Our client aimed to develop a drug for a defined population of cancer patients where their ICD fails, in order to enhance it and make it work again.

    To support our client, Alcimed evaluated three potential subfields in ICD, and showed which induction field is highly developed based on scientific rationales. Next, we mapped research global hotspots and evaluated their maturity. Finally, we evaluated the maturity and progress of key players, and assessed partnership opportunities for the client.

    The recommendations allowed our client to identify potential partners to collaborate with in future drug development, and the results served as base for their future strategic orientation.

Our latest articles in oncology


Meet Volker

Great Explorer Oncology

Volker is Alcimed’s Great Explorer Oncology, based in our office in Cologne. He supports Alcimed and our clients with his Oncology experience.

He has more than 10 years’ expertise in oncology in consulting and conducted more than 80+ Oncology-related projects.

Volker received his degree of Dr. rer. nat. at the University of Potsdam and the Max-Planck-Institute of Molecular Plant Physiology in Potsdam and worked for 4 years as a post-doctoral fellow in molecular and cell biology at INRA Versailles.